GLP-1 receptor agonists consistently reduced asthma exacerbations and healthcare utilization in observational studies, with benefits persisting even after adjusting for BMI and blood sugar changes. Preclinical models revealed direct airway effects including reduced inflammation, hyperresponsiveness, and epithelial cytokine signaling. This dual mechanism discovery challenges the assumption that respiratory benefits stem solely from weight reduction. The finding carries significant implications for the 25 million Americans with asthma, particularly the growing subset with obesity-associated asthma. GLP-1RAs like semaglutide and tirzepatide are already prescribed widely for diabetes and weight management, creating potential for immediate off-label application. However, the evidence remains largely observational with significant confounding factors, and preclinical findings may not translate due to species differences in receptor expression. The review highlights a critical knowledge gap: whether these medications benefit asthma patients without metabolic dysfunction. While promising, this represents incremental rather than paradigm-shifting evidence, requiring dedicated randomized trials to establish causality and identify optimal candidate populations.